Remarkably, though, treatment of both cancer cell lines SU.86.86 and T3M4 with the CCR4 antagonist (C021) decreased paxillin phosphorylation in a time-dependent manner (Figure 3, H and I, and Supplemental Figure 6, H and I). Here, CCR4 is linked to cancer.